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Abstract
Background: Recent investigations by the Ministry of Health of Cambodia suggest that counterfeit medicines have
been introduced into the pharmaceutical market in tampered packaging. To further explore this possibility, an
interview survey was conducted at the wholesaler level to investigate the medicinal supply chain in Cambodia.
Methods: Managing executives of 62 (83.8%) registered wholesalers of modern medicines in Cambodia were
interviewed in 2009 on their knowledge of, perception on, and practices related to counterfeiting issues through a
semi-structured questionnaire.
Results: According to our findings, 12.9% of the wholesalers had encountered counterfeit medicine. However, they
demonstrated a variety of perceptions regarding this issue. A majority (59.7%) defined counterfeit medicines as
medicines without registration, while other definitions included medicines that were fraudulently manufactured,
medicines without a batch/lot number, those containing harmful ingredients or a reduced amount of active
ingredients, and expired medicines. Additionally, 8.1% responded that they did not know what counterfeit
medicines were.
During procurement, 66.1% of the wholesalers consider whether the product is registered in Cambodia, while
64.5% consider the credibility and quality of the products and 61.3% consider the reputation of the manufacturers.
When receiving a consignment, 80.6% of wholesalers check the intactness of medicines, 72.6% check the
specification and amount of medicines, 71% check Cambodian registration, 56.5% check that the packaging is
intact, 54.8% check batch and lot numbers, 48.4% check the dates of manufacture and expiration, and 9.7% check
analytical certificates.
Out of 62 wholesalers, 14.5% had received medicines that arrived without packages or were separated from their
packaging and had to be repacked before distribution. Significant statistical association was found between
wholesalers who received medicines separately from their packs/containers and who consider their belief on
reliability of pharmaceutical products of certain manufacturing country during procurement (Chi-square: 12.951, P =
0.002). When wholesalers divide medicines from larger packs into smaller ones, 54.8% use packaging purchased
from local markets.
Conclusion: A number of wholesalers think counterfeit medicines are medicines without registration, and/or do
not have any uniform ideas on the issue and what to do, when they find or suspect counterfeits. Furthermore,
their strict adherence to anti-counterfeiting measures is urgently needed.
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Like many other public health problems, the counterfeit-
ing of medicine is an important issue that should receive
careful attention in developing countries. In Cambodia,
the Ministry of Health (MoH) and law enforcing agen-
cies first became aware of the issue in the late 1990s,
and since then, the government in cooperation with sev-
eral international organizations (such as World Health
Organization (WHO), INTERPOL, USAID, US Pharma-
copeial Convention (USP), Japan Pharmaceutical Manu-
facturers Association (JPMA) etc.) has been struggling
to stamp out the problem and to prevent further
damage to communities [1-7]. However, the point at
which to start tackling this problem is still unclear in
many parts of the world, as well as in Cambodia [8].
Invariably, after manufacture, medicinal products are
transferred through several hands to reach their custo-
mers. Even in developed countries, distributors are iden-
tified as the most critical link in the legitimate
pharmaceutical supply chain and the point of entry for
most counterfeit medicines [8,9]. Counterfeit medicines
have been discovered at various points in the supply
chain: at the industry level, at the wholesale level, the
packaging level, and so forth [10,11]. In the developing
world, the situation could be even worse, especially
where regulations are weakly enforced [12].
According to the MoH, Cambodia, counterfeit medi-
cine is one, which is deliberately produced with incor-
rect or wrong active ingredients or without active
ingredients or unregistered, in which, amounts of active
ingredients are deliberately outside the defined pharma-
copoeial standard or which is deliberately and fraudu-
lently mislabelled with respect to the identity source or
with fake packaging, or repacked or produced by
unauthorized person [2]. In 2001 and 2004, the MoH,
Cambodia, in cooperation with WHO reported the pre-
valence of 10.43% and 21.13% counterfeit medicines
respectively among some essential medicines (such as
antimalarials, analgesics, antibiotics, vitamins and ster-
oids) in the country [2,13]. A study conducted during
2002-2003, reported 92.7% substandard aspirin in pri-
vate outlets [14]. In 2006, another study found 58%
counterfeit and substandard antimalarials in licensed
and 75% in non-licensed outlets [15]. In many cases, the
counterfeit products identified in retail shops were in
open packages and/or were unregistered [7,16]. Some of
the counterfeit medicines were identified as two or
more physical types of medicines and active ingredients
were mixed together in one container or box [7]. These
discoveries prompted the Cambodian Ministry of Health
to look into the pharmaceutical supply chain, emphasis-
ing issues of counterfeiting. In this connection, the
Department of Drugs and Food (DDF), MoH, Cambodia
conducted a face-to-face interview survey among
pharmaceutical wholesalers in collaboration with Kana-
zawa University, Japan, with the objective of assessing
wholesalers’ sensitisation to counterfeit issues and obser-
ving their compliance with DDF’s guidelines. It might be
worth mentioning that DDF is the medicine regulatory
authority in-charge of monitoring the pharmaceutical
sector in Cambodia.
Methods
This cross-sectional survey was conducted in July 2009
on signing an agreement between Ministry of Health,
Cambodia and Japan Pharmaceutical Manufacturers
Association (JPMA) and after an ethical clearance
approval of Kanazawa University, Japan. Advice was also
sought in this regard from local Cambodian institutions.
A list of private sector wholesalers was prepared before-
hand in consultation with the DDF. All of the wholesa-
lers in the list were contacted for face-to-face
interviews, excluding those who might have changed
addresses or closed down their businesses. Based on
their addresses in different locations of the capital city,
Phnom Penh, the list was then distributed to two differ-
ent teams of interviewers. Each team consisted of a
Japanese research investigator and two locally recruited
Cambodian members.
A semi-structured questionnaire was prepared (based
on a questionnaire survey conducted in 2008 at retail
pharmacy level in Cambodia) for the interview, focusing
on wholesalers’ practices and perceptions surrounding
counterfeit medicine issues, which could be categorised
as questions related to the following: 1) attributes of the
respondent and wholesale business, 2) perception and
practices related to procurement and storage of medi-
cines, 3) perceptions and practices related to medicine
quality, and 4) observation on handling medicines in the
ware house [17]. The questionnaire was translated into
the Khmer language for Cambodian respondents. The
questionnaire was then discussed with the Japanese and
local researchers, and staff of Ministry of Health.
All participants in the interview teams were provided
with training to avoid team bias and were instructed
that the interviewers should not provide leading ques-
tions during interviews. The questionnaire was then pre-
tested among different wholesalers in Phnom Penh and
edited before starting the final survey. Interview teams
contacted managing executives of wholesale businesses.
Interviewers explained the reason for the study to the
respondents and requested their cooperation. A small
gift was given as a token of appreciation to each inter-
viewee, and informed consent was obtained before
proceeding.
The respondents were encouraged to reply honestly
and without fear. Interviewers explained to respondents
that there was no threat of future action based on their
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maintaining utmost confidentiality in accordance with
the medical ethics committee of Kanazawa University.
Interviews were conducted in Khmer language, however,
in some cases, when respondents were foreigners, inter-
views were taken in English.
Multiple answers were accepted for some of the ques-
tions. For the observational section of the questionnaire,
interviewers visited the warehouses of the wholesalers
after obtaining respondents’ permission. The inter-
viewers checked whether or not medicines were kept
well arranged according to medicine types and/or classi-
fication; cleanliness, tidiness and sufficiency of space in
the stores were assessed subjectively on agreement of
the members of the interview team. The physical prop-
erties, such as size, shape, colour, printed information,
emboss, hologram etc. of three or four samples of medi-
cines from the shelves in the warehouses were examined
to find out presence of two or more types of medicines
mixed together in one container or box, presence of
expired medicines and medicines without registration
labels. Each of the filled-out questionnaires was given a
specific interview number immediately following its
completion.
Data analysis was performed using SPSS release 17.0.0
(Chicago, SPSS Inc.). Where appropriate, Fisher’se x a c t
test was performed to identify whether there was any
significant relation among the variables of perceptions
and practices. However, only relevant significant associa-
tions are mentioned in the results section. Statistical sig-
nificance was set at the level of 5%.
Results
A total of 62 wholesalers were interviewed. The mean
age of the respondents was 38 years (mode: 36 yrs; SD:
10.89) and the majority (50.81%) of them were male.
Among those interviewed, 35% were company owners;
48% were directors, managers, or administrative heads;
8% were general staff; and 8% held other positions.
Their educational background varied; 27% of the
respondents were pharmacists and 8% were doctors,
whereas 21% had some sort of business degree and the
rest (44%) were from other educational backgrounds. A
large number (40%) of the wholesalers had a staff of
fewer than ten people, and 56% had been operating
their businesses for less than five years in Cambodia.
Suppliers and customers
When the wholesalers were asked about the primary
sources of their products, 95.2% (n = 59) of them
responded that they procure their products directly
from foreign manufacturers, whereas 12.9% (n = 8) of
them procure them through an importing agent; 1.6% (n
= 1) of them obtain products from another distributor
or supplier, and 6.5% (n = 4) of them procure products
from domestic manufacturers. The majority (96.8%, n =
60) of the wholesalers said that their customers were
pharmacies (i.e.: legal outlets, supposed to be run by
pharmacists) and Depot A (i.e.: legal outlets, supposed
to be run by assistant pharmacists, those who received
three years of pharmaceutical training) and Depot B (i.
e.: legal outlets, supposed to be run by retired doctors
or nurses) types of outlets. Additionally, 80.6%, (n = 50)
of them distribute medicines to private clinics and prac-
titioners. However, 8.1% (n = 5) of them supply pro-
ducts to any drug stores regardless of license, and 4.8%
(n = 3) of them sell to another wholesaler. The number
of medicinal products that they were dealing with varied
from 3 to 450 (mean: 80.94; SD: 98.18).
Sixty (96.7%) of the wholesalers always procure their
medicines from the same manufacturer(s)/company/
companies, mainly due to their trust (73.3%, n = 44) of
these companies and the quality of products (71.7%, n =
43); 18.3%, (n = 11) procure their medicines from the
same supplier due to reasonable price, and 6.7% (n = 4)
of them do so because of supplier can provide a wide
variety of medicines. Occasionally, the wholesalers had
refused to purchase medicines from some suppliers/
sources; their most common explanation for this was
that the suppliers were not trustworthy (55.6%, n = 25)
in their business dealings. Similarly, when they refused
to supply to a customer, it was most often the custo-
mers’ t r u s t w o r t h i n e s st h a tm a d et h e mt od os o( 5 9 . 1 % ,
n = 13).
Procurement
In response to the question regarding their considera-
tions when procuring medicine(s), a majority of whole-
salers (66.1%, n = 41) reported that they consider
Cambodian registration, while 62.9% (n = 39) of them
consider the quality and credibility of the products;
61.3% (n = 38) of them consider the reputation of the
manufacturer, 50% (n = 31) consider demands of custo-
mers, 37.1% (n = 23) consider profits, 21% (n = 13) con-
sider the reputation of the manufacturing country, and
16.1% (n = 10) consider the recommendations of the
retailers (sellers). However, when receiving a consign-
ment, 80.6% (n = 50) of respondents check any damage
of the medicines due to shipment or handling and make
sure of their intactness, 72.6% (n = 45) of them check
the specification and amount, 71% (n = 44) check Cam-
bodian registration, 56.5% (n = 35) check the intactness
and any damage of packaging, 54.8% (n = 34) check the
batch and lot number, 53.2% (n = 33) check the name
of the manufacturer, 48.4% (n = 30) check the dates of
manufacture and expiration, 27.4% (n = 17) check the
brand name, and 9.7% (n = 6) of them check the analy-
tical authorisation of the products (Figure 1). In
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be accompanied with certificates of analysis (COA)
issued by the manufacturers, which should be based on
the results obtained from the analysis of the lots/batches
that are being shipped [18]. Those who consider regis-
tration or check registration in the consignments were
asked about their reasons for doing so. In reply, 81.6%
(n = 40) of them reported that they were following the
instruction of authorities, while 67.3% (n = 33) of them
said that they do so because of their belief that registra-
tion guarantees quality, and 8.2% (n = 4) of them
ascribed the practice to their experience of low quality
in unregistered medicines.
Packaging practice
In response to a question, 14.7% (n = 9) of the wholesa-
lers reported that they had received medicines separately
from their packaging or with missing packaging. A sig-
nificant statistical association was found between whole-
salers who received medicines outside of their packaging
and those who consider the reputation of the manufac-
turing country during procurement (Chi-square: 12.951,
P = 0.002)
In situations where wholesalers needed to divide med-
icines from large packs or containers in order to supply
a portion of the medicine to a customer, 54.8% (n = 34)
of them repack medicines in ordinary, commercially
purchased paper or plastic packaging. By comparison,
11.3% (n = 7) of the respondents repack medicine in
another empty container belonging to the same medi-
cine or same manufacturer, and 30.6% (n = 19) do not
sell medicines in such cases (Figure 2).
In another question, wholesalers were asked what they
usually do if they need to repack two or more kinds of
medicines that treat the same disease or bear the same
active ingredient in cases where they will be sold to a sin-
gle customer, provided that there are not enough packs
or containers available. Four (6.5%) respondents replied
that they re-pack medicines in packaging purchased from
markets, 9 (14.5%) said they use another container for
the same medicine, and 47 (75.8%) said they always sup-
ply medicines only in genuine containers or packs (Figure
3). Our findings also suggest that medicines are some-
times mixed in the same package. Detailed observational
findings are summarised in Table 1.
Counterfeit medicine issue
Eight (13.3% of 60) of the respondents said that they
had previously seen counterfeit medicines and they
identified those from their printed lebels, addresses or
Others
Recommendations by sellers
Reputation of manufacturing country
Higher profit 
Demands of the customers
Reputation of manufacturer(s)
Better quality and credibility of products
Cambodian registration 
0 1 02 03 04 05 06 07 08 09 0 1 0 0
Wholesalers' consideration during procurement (%)
66.1
62.9
61.3
50.0
37.1
21.0
16.1
8.1
Others
Analytical Certificates
Brand name 
Dates of manufacture and expiration
Name of manufacturer(s)
Batch/Lot number
Intactness of packaging
Cambodian registration
Specifications and amount
Intactness of medicines
0 1 02 03 04 05 06 07 08 09 0 1 0 0
Check points during receiving consignments (%)
80.6
72.6
71.0
56.5
54.8
53.2
48.4
27.4
9.7
11.3
N=62
Figure 1 Wholesalers’ considerations and checkpoints during procurement.
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acteristics of package, logo and having no registration
number. When they were asked about their perceptions
of counterfeit medicines, a majority (59.7%, n = 37) of
respondents expressed the opinion that counterfeit
medicines are medicines having no registration and/or
were fraudulently manufactured (56.5%, n = 35) (Figure
4). However, at least eight (12.9%) of them did not have
any clear conception of the meaning of the term. Five of
them replied that they did not know what counterfeit
Packs 
purchased
from market
Packs of 
manufacturer
Don't
repack 
mixed 
together
Others
0
10
20
30
40
50
60
70
80
P
e
r
c
e
n
t
6.5
14.5
75.8
4.8
N=62
Figure 3 How do wholesalers repack two or more kinds of medicines?.
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packs
Repack in 
packs
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Do not sell 
such medicines
Others
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54.8
30.6
8.1
N=62
Figure 2 How do wholesalers repack medicines when they need to divide large packs?.
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Page 5 of 8medicines were, and three others replied that counterfeit
medicines are medicines with reduced amounts of active
ingredients, cheaper medicines, or expired medicines.
According to the wholesalers’ statements, if they
received any counterfeit medicine, 72.4% (n = 42) of
them would report such a case to the regulatory autho-
rities, and 27.6% (n = 16) of them would either send the
medicine back to its source or separate and discard the
medicine without informing the authorities.
To assess wholesalers’ awareness of regulations,
respondents were asked whether they were aware that
they must inform DDF before dispatching any consign-
ment, and it was found that 35% (n = 21) of them did
not know this requirement. A statistically significant
association was found between wholesalers who were
n o ta w a r eo ft h er e q u i r e m e n ta n dt h o s ew h od on o t
consider Cambodian registration during procurement
(Chi-square: 4.29, P = 0.05).
Discussion
Most often, pharmaceutical products find their way
from manufacturers to pharmacies through wholesalers.
However, there are cases where the wholesalers sell
medicines to secondary or tertiary wholesalers or distri-
butors [19-21]. The findings of this survey suggest that
wholesalers procure their products from different
sources, suppliers and distributors and that these multi-
ple actors in the supply chain may potentially increase
the risk of intrusion of counterfeit products if regulation
is limited. The survey was limited in that it was not con-
ducted by professional interviewers, where, two teams
were deployed for the interviews and interviews were
conducted in both Khmer and English languages; as
such, it was not possible to completely rule out the pos-
sibility of interviewer bias. Nevertheless, to minimise
such bias, training and feedback discussions were held
after the interviews. Another limitation of the survey is
that it was designed on certain background of counter-
feit findings of the country and may not cover compre-
hensively wholesalers’ perception and practices on
dealing with medicines. We believe that the results at
least represent baseline information on Cambodian
wholesalers and could help Cambodian regulators take
future steps.
This survey has shown that cooperation and trust
among different stakeholders in the supply chain might
Table 1 Results of observation of storage practice
Observation Yes
1 Medicines arranged in the shelves according to different classification, and not mixed together (n = 52) 38 (73.1%)
2 Medicines are stored maintaining tidiness and cleanliness (n = 51) 43 (84.3%)
3 Is there sufficient space in the store? (n = 52) 44 (84.6%)
4 Does the wholesaler maintain stock records for different kinds of medicines? (n = 52) 48 (92.3%)
5 Are there medicines mixed together with other types of medicines in a container or box? (n = 51) 6 (11.8%)
6 Presence of expired medicine on the shelves with other medicines (n = 52) 0
7 Presence of medicines without registration labels mixed with other medicines with registration on the shelves (n = 52) 1 (1.9%)
Others
Do not have an idea
Expiration date over 
Containing harmful ingredients
Having no batch/lot no.
Containing less amount of active ingredient(s)
Fraudulently manufactured
Having no registration
-
0
5
1
0
1
5
2
0
2
5
3
0
3
5
4
0
4
5
5
0
5
5
6
0
6
5
7
0
9
5
1
0
0
Percent
59.7
56.5
27.4
21
19.4
8.1
8.1
17.7
N=62
Figure 4 Wholesalers’ conceptions of counterfeit medicines.
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efforts to maintain quality. It is encouraging that most
of the wholesalers consider Cambodian registration dur-
ing procurement when receiving consignments because
medicines without registration were significantly asso-
ciated with counterfeit medicines in an earlier study
[16]. Nevertheless, only a few respondents noted that
they check analytical certificates.
Some of the wholesalers confirmed that they some-
times receive medicines separately from their packaging
and that they repack them before resale. This finding
was also associated with wholesalers’ consideration of
the reputations of the manufacturing countries during
procurement. This might be important information
because package condition and foreign origin were pre-
viously identified as other influential factors for counter-
feit medicines [16]. Moreover, our survey findings
suggest that some of the wholesalers repack medicines
by procuring extra containers from local markets,
although DDF does not allow wholesalers to import or
procure medicines without packages, nor are they
allowed to repack medicines. It may happen that due to
wholesalers trust and believe on products of some of the
manufacturing countries, they slip from checking or
over look the packaging requirements during receiving
medicinal consignments. If packing or repacking at the
wholesaler level is unavoidable due to the convenience
of transportation and/or distribution, we suggest existing
regulation should be reinforced to require proper label-
ling to protect genuine medicines.
Some of the respondents in this survey did not have a
clear conception of counterfeit medicines and were una-
ware of what they should do if they suspect any coun-
terfeits. In these situations, there is a strong need to
orient and sensitise wholesalers to issues of counterfeit
medicine. Anti-counterfeit measures need to be incorpo-
rated into a set of guidelines to be developed for whole-
salers [22]. This survey shows that wholesalers’
businesses are licensed and regulated by a number of
authorities, which makes them difficult to monitor [19].
The association found among wholesalers who were
unaware of up-to-date regulatory information and those
do not consider Cambodian registration during procure-
ment may signify that some information gaps exist
among stakeholders. To strengthen the regulatory sys-
tem, information-sharing components in the form of
advocacy workshops or meetings should be arranged on
a regular basis.
Conclusion
A major proportion of wholesalers are not properly
informed on issues of counterfeit medicine and how to
handle such cases. To protect the supply chain of phar-
maceutical products from the intrusion of counterfeit
medicines, distributors and wholesalers should be
oriented and sensitised to countermeasures against
counterfeit medicines.
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